arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

download Export Data

BriaCell Therapeutics Corp.

BCTX

$3.65 ▲ +0.19 (+5.49%) at close

21 Visible periods

19 Metrics

Absolute Benchmarks

Price Chart

Health

Fair

Neutral Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, BriaCell Therapeutics Corp. shows solid but mixed fundamentals. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $26.5M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC None

FCF / Share $-0.97 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

21-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-7.16M

↓ -16.9% —

FCF / Share Free cash flow per share

$-0.97

↑ +65.9% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

Health Breakdown

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
EPS Growth YoY (%)	39.6% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-10.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-1877.3% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	-228.2% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	-26780.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	7.8% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	N/M	96.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	-16.9% Weak ↑ Weak Improving Year-over-year change in net income	-14.8% Weak ↑ Weak Improving Year-over-year change in net income	-41.3% Weak ↑ Weak Improving Year-over-year change in net income	-566.4% Weak Weak Year-over-year change in net income	N/M	44.3% Excellent Excellent Year-over-year change in net income	N/M	49.8% Excellent Excellent Year-over-year change in net income	N/M	4.9% Caution ↑ Caution Improving Year-over-year change in net income	N/M	-437.1% Weak ↓ Weak Declining Year-over-year change in net income	51.1% Excellent Excellent Year-over-year change in net income	N/M	96.0% Excellent Excellent Year-over-year change in net income	—	—	—	—	—	—
FCF Growth YoY (%)	—	—	-1466.6% Weak Weak Year-over-year change in free cash flow	—	—	—	45.1% Excellent Excellent Year-over-year change in free cash flow	—	—	—	-108.5% Weak Weak Year-over-year change in free cash flow	—	—	—	-95.6% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
FCF / Net Income (x)	0.98x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.01x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	—	—	1.20x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	3.32x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	-1.27x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	4.51x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	3.20x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	7.38x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.48x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	-0.23x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.06x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
Return on Invested Capital (%)	—	—	—	—	—	—	—	—	—	—	—	—	76.1% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	276.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-40.0% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-32.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-17.5% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-114.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-28.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-22.4% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-63.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-37.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-76.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-49.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-98.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-148.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-80.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-45.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-19.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-13.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-14.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-12.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	—	—	—	—	—	—	—	—	—	—	—	—	83.1% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+454%)	—	-10.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-171%)	-4.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-129%)	-100.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-770%)	67.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+353%)	—	—	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2333.82x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-6.88M	$-29.90M	$-2.71M	$-10.49M	$-12.46M	$-5.01M	$-5.79M	$-862.09K	$-935.69K	$-6.24M	$-13.65M	$-21.25M	$-28.17M	$-33.50M	$-37.45M	$-41.04M	—	—	—	$-57.27M	—

📊 What does each share earn? 5 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
Basic EPS, GAAP (USD)	$-0.99	$-2.58	$-4.35	$4.89	$-1.64	$-2.33	$-0.22	$-40.32	$0.11	$-0.71	$0.38	$-0.15	—	$-0.77	$-0.07	—	—	$0.71	$-1.81	—	—
Free Cash Flow per Share (USD)	$-0.97	$-2.84	$-4.09	—	—	—	$-0.26	—	—	—	$-0.48	—	—	—	$-0.23	—	$-0.31	$-0.16	$-0.12	—	—
Book Value per Share (USD)	—	—	—	—	—	—	—	—	—	—	—	—	$-0.38	$-0.08	$0.67	$0.67	$0.65	$1.04	$0.10	$1.81	—
Tangible Book Value per Share (USD)	—	—	—	—	—	—	—	—	—	—	—	—	$-0.38	$-0.08	$0.67	$0.67	$0.65	$1.04	$0.10	$1.81	—
Basic Weighted Avg Shares (shares)	7.25M	2.80M	1.88M	—	3.74M	2.70M	26.64M	—	15.98M	15.98M	15.98M	—	15.52M	15.52M	15.52M	—	15.36M	15.79M	15.24M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
Working Capital (USD)	$21.80M	$28.99M	$8.03M	$15.95M	$10.45M	$1.93M	$3.23M	$-3.81M	$-1.23M	$7.82M	$17.36M	$25.15M	$28.12M	$33.27M	$37.25M	$41.41M	—	—	—	$57.24M	—
Total Equity (USD)	—	—	—	—	—	—	—	—	—	—	—	—	$-5.89M	$-1.28M	$10.33M	$10.33M	$9.96M	$16.43M	$1.58M	$27.67M	$-2.74M

📋 What is driving earnings? 3 metrics

Metric	Q3 FY2026 Apr 30, 2026 10-Q ↗	Q2 FY2026 Jan 31, 2026 10-Q ↗	Q1 FY2026 Oct 31, 2025 10-Q ↗	Q4 FY2025 Jul 31, 2025 10-K ↗	Q3 FY2025 Apr 30, 2025 10-Q ↗	Q2 FY2025 Jan 31, 2025 10-Q ↗	Q1 FY2025 Oct 31, 2024 10-Q ↗	Q4 FY2024 Jul 31, 2024 10-K ↗	Q3 FY2024 Apr 30, 2024 10-Q ↗	Q2 FY2024 Jan 31, 2024 10-Q ↗	Q1 FY2024 Oct 31, 2023 10-Q ↗	Q4 FY2023 Jul 31, 2023 10-K ↗	Q3 FY2023 Apr 30, 2023 10-Q ↗	Q2 FY2023 Jan 31, 2023 10-Q ↗	Q1 FY2023 Oct 31, 2022 10-Q ↗	Q4 FY2022 Jul 31, 2022 10-K ↗	Q3 FY2022 Apr 30, 2022 10-Q ↗	Q2 FY2022 Jan 31, 2022 10-Q ↗	Q1 FY2022 Oct 31, 2021 10-Q ↗	Q4 FY2021 Jul 31, 2021 10-K ↗	Q4 FY2020 Jul 31, 2020 10-K ↗
Depreciation Expense (USD)	$29.19K	$22.84K	$22.84K	$22.84K	—	—	$22.84K	—	—	—	—	—	$3.82K	$3.82K	$3.82K	—	$3.82K	$3.82K	$3.82K	—	—
Net Income, GAAP (USD)	$-7.16M	$-7.22M	$-8.20M	$-8.09M	$-6.13M	$-6.29M	$-5.80M	$-1.21M	$1.72M	$-11.29M	$6.00M	$-2.42M	$-4.90M	$-11.88M	$-1.11M	$-450.35K	$-10.02M	$11.16M	$-27.53M	—	—
Operating Cash Flow (USD)	$-7.02M	$-7.97M	$-7.70M	$-8.13M	—	—	$-6.96M	$-4.04M	—	—	$-7.61M	$-10.92M	—	—	$-3.54M	$-3.33M	$-4.82M	$-2.56M	$-1.78M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 21 quarters

BriaCell Therapeutics Corp.

Analytical Summary

21-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare BCTX with peers